Ranbaxy Laboratories and Sun Pharmaceutical Industries announced that they have received an intimation pertaining to communication from the Competition Commission of India (CCI) in respect of the proposed combination between Sun Pharma and Ranbaxy Laboratories.

Both the companies received direction under Section 29(2) of the Competition Act, 2002 from CCI directing them to publish the details of the proposed combination within 10 working days from Aug. 27, 2014 in Form IV contained in Schedule II to the Combination Regulations.

Shares of Ranbaxy Laboratories declined Rs 3.15, or 0.49%, to trade at Rs 645.60. The total volume of shares traded was 16,845 at the BSE (10.16 a.m., Thursday).

Sun Pharmaceutical Industries shares declined Rs 3.15, or 0.37%, to trade at Rs 858.65. The total volume of shares traded was 18,988 at the BSE (10.16 a.m., Thursday).